Medications

Atezolizumab prolongs survival in NSCLC with PD-L1 expression

(HealthDay)—For patients with non-small cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) expression, treatment with atezolizumab results in longer overall survival than chemotherapy, according to a study ...

page 1 from 8